Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Oliver Sartor MD Advisory Board

Roxana S. Dronca MD Advisory Board

Elizabeth Smyth MD Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · June 16, 2017

Key Trials on Brain Metastases From ASCO 2017

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Manmeet Ahluwalia MD, FACP, MBA

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Related Items

Dabrafenib Plus Trametinib in Patients With BRAF(V600)–Mutant Melanoma Brain Metastases (COMBI-MB)
Improved Survival of Patients With Melanoma Brain Metastases in the Era of Targeted BRAF and Immune Checkpoint Therapies

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

Commentary · December 08, 2022
featured

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

Commentary · December 06, 2022
featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Commentary · December 06, 2022
story of the week

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

JAMA Oncol · December 05, 2022

updated
story of the week

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

J. Clin. Oncol · December 05, 2022
featured

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Neuro-oncology · November 29, 2022
story of the week

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

JAMA Oncol · November 22, 2022

updated
featured

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Neuro-oncology · November 16, 2022
story of the week

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

J. Clin. Oncol · November 15, 2022

updated
story of the week

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

J. Clin. Oncol · November 14, 2022

Brain Cancer

Key Trials on Brain Metastases From ASCO 2017

Additional Info

Brain Cancer Center of Excellence

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

Further Reading

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

Long-Term Outcomes After Perioperative Chemotherapy and Nivolumab for NSCLC

Induction Chemotherapy Followed by Standard Chemoradiotherapy vs Standard Chemoradiotherapy Alone for Locally Advanced Cervical Cancer

Hematologic Cancer After Gene Therapy for Cerebral Adrenoleukodystrophy

Related Videos